L3VLUP
ProSign in

CCCC · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CCCCARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CCCC
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterCCCCARGX
Q3 2020none listed holders, n.a.8 holders, $3.6bn
Q4 20201 holders, $5.5m7 holders, $4.1bn
Q1 20211 holders, $2.0m8 holders, $4.1bn
Q2 20211 holders, $981k9 holders, $4.6bn
Q3 2021none listed holders, n.a.8 holders, $4.5bn
Q4 20211 holders, $2.6m9 holders, $5.3bn
Q1 20221 holders, $12m8 holders, $5.3bn
Q2 20222 holders, $3.2m13 holders, $6.5bn
Q3 2022none listed holders, n.a.14 holders, $5.3bn
Q4 20221 holders, $338k13 holders, $5.5bn
Q1 20232 holders, $369k13 holders, $5.9bn
Q2 20231 holders, $73k18 holders, $6.6bn
Q3 2023none listed holders, n.a.21 holders, $8.7bn
Q4 2023none listed holders, n.a.17 holders, $6.3bn
Q1 20242 holders, $401k13 holders, $6.8bn
Q2 20242 holders, $226k14 holders, $7.9bn
Q3 20241 holders, $160k13 holders, $10.7bn
Q4 20242 holders, $177k14 holders, $12.3bn
Q1 20251 holders, $45k17 holders, $11.8bn
Q2 20251 holders, $40k18 holders, $10.8bn
Q3 20251 holders, $62k16 holders, $13.8bn
Q4 20251 holders, $53k16 holders, $14.8bn
Q1 20261 holders, $74k11 holders, $12.3bn
Q2 2026none listed holders, n.a.14 holders, $15.0bn
CCCC

C4 Therapeutics Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
17
Reported value
$6.3bn
Buyers
12
Sellers
6

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2023

Among the 17 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only CCCC (0)

None.

Only ARGX (17)

Artisan Partners LP, Balyasny Asset Management LLC, Capital World Investors, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Point72 Asset Management LP, T. Rowe Price Associates Inc, Verition Fund Management LLC, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →